Abstract
Aims Death due to cardiovascular diseases (CVD) increased significantly in China. One way to reduce CVD is to identify people at risk and provide targeted intervention. We aim to develop and validate a CVD risk prediction model for Chinese males (CVDMCM) to help clinicians identify those at risk of CVD and provide targeted intervention.
Methods and Results We conducted a retrospective cohort study of 2331 Chinese males without prior CVD to develop and internally validate the CVDMCM. These participants had a baseline physical examination record (2008-2016) and one revisit record by September 2019. With the full cohort, we used single factor cox regression to examine each candidate predictor adjusted for age. 16 sequential prediction models were built on significant predictors. CVDMCM was selected based on the Akaike information criterion, the area under the ROC curve, and the percentage of variation in outcome values explained by the model (R2). This model, the Framingham CVD risk model, and the Wu’s simplified model were all validated by bootstrapping with 1000 repetitions. CVDMCM’s C statistics (0.779, 95% CI: 0.733-0.825), D statistic (4.738, 95% CI: 3.270-6.864), and calibration plot demonstrated that CVDMCM outperformed the other two models.
Conclusions We developed and internally validated CVDMCM, which predicted 4-year CVD risk for Chinese males with a better performance than Framingham CVD model and Wu’s simplified model. In addition, we developed a web calculator for physicians to conveniently generate CVD risk scores and identify those with a higher risk of CVD. We believe CVDMCM had great potential for clinical usage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Key Research and Development Program of China [Grant Number 2020YFC2008000; principal investigator CZ] and Major Technology Innovation of Hubei Province [Program No. 2019ACA141]. The funding source was not involved in the process of this study and article preparation. The contents do not reflect official views from the Hubei provincial government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Medical Ethics Committee at Tongji Medical College, Huazhong University of Science and Technology who waived the written informed consents (TJ-IRB20191215).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.